LFG
KYMR icon

Larson Financial Group’s Kymera Therapeutics KYMR Stock Holding History

Larson Financial Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80K Sell
961
-103
-10% -$8.16K ﹤0.01% 1099
2025
Q4 		$82.8K Buy
1,064
+287
+37% +$19.4K ﹤0.01% 998
2025
Q3 		$44K Buy
777
+349
+82% +$15.7K ﹤0.01% 1215
2025
Q2 		$18.7K Buy
+428
New +$14.7K ﹤0.01% 1521

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Larson Financial Group's KYMR Position: Q1 2026 in Review

Larson Financial Group reduced its Kymera Therapeutics (KYMR) stake by 9.7% in Q1 2026, selling an estimated $8.16K and leaving 961 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

Larson Financial Group first reported a position in KYMR in Q2 2025 and has held it in 4 quarters since. The position peaked at $82.8K in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Larson Financial Group held 961 shares of Kymera Therapeutics worth $80K as of Q1 2026.
  • Larson Financial Group sold 103 Kymera Therapeutics shares in Q1 2026, an estimated $8.16K.
  • Kymera Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #1099 holding.
  • Larson Financial Group first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Kymera Therapeutics position peaked at $82.8K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.